Aditi Nayak1, Colin Neill2, Robert L Kormos3, Luigi Lagazzi3, Indrani Halder4, Charles McTiernan4, Jennifer Larsen2, Ana Inashvili1, Jeffrey Teuteberg3, Timothy N Bachman5, Karen Hanley-Yanez4, Dennis M McNamara6, Marc A Simon7. 1. Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. 2. School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. 3. Heart and Vascular Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. 4. Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. 5. Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA; Department of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. 6. Heart and Vascular Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA; Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. 7. Heart and Vascular Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA; Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA; Department of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. Electronic address: simonma@upmc.edu.
Abstract
BACKGROUND: Right ventricular failure (RVF) complicates 9% to 44% of left ventricular assist device (LVAD) implants post-operatively. Current prediction scores perform only modestly in validation studies, and do not include immune markers. Chemokines are inflammatory signaling molecules with a fundamental role in cardiac physiology and stress adaptation. In this study we investigated chemokine receptor regulation in LVAD recipients who develop RVF. METHODS: Expression of chemokine receptor (CCR) genes 3 to 8 were examined in the peripheral blood of 111 LVAD patients, collected 24 hours before implant. RNA was isolated using a PAXgene protocol. Gene expression was assessed using a targeted microarray (RT2 Profiler PCR Array; Qiagen). Results were expressed as polymerase chain reaction (PCR) cycles to threshold and normalized to the average of 3 control genes, glyceraldehyde phosphate dehydrogenase (GAPDH), hypoxanthine phosphoribosyltransferase 1 (HPRT1) and β2-microglobulin (B2M). Secondary outcomes studied were 1-year mortality and long-term RV failure (RVF-LT). RESULTS: CCR3, CCR4, CCR6, CCR7 and CCR8 were downregulated in LVAD recipients with RVF. Within this cohort of patients, CCR4, CCR7 and CCR8 were further downregulated in those who required RV mechanical support. In addition, under-expression of CCR3 to CCR8 was independently associated with an increased risk of mortality at 1 year, even after adjusting for RVF. CCR expression did not predict RVF-LT in our patient cohort. CONCLUSIONS: Pre-LVAD CCR downregulation is associated with RVF and increased mortality after implant. Inflammatory signatures may play a major role in prognostication in this patient population.
BACKGROUND:Right ventricular failure (RVF) complicates 9% to 44% of left ventricular assist device (LVAD) implants post-operatively. Current prediction scores perform only modestly in validation studies, and do not include immune markers. Chemokines are inflammatory signaling molecules with a fundamental role in cardiac physiology and stress adaptation. In this study we investigated chemokine receptor regulation in LVAD recipients who develop RVF. METHODS: Expression of chemokine receptor (CCR) genes 3 to 8 were examined in the peripheral blood of 111 LVADpatients, collected 24 hours before implant. RNA was isolated using a PAXgene protocol. Gene expression was assessed using a targeted microarray (RT2 Profiler PCR Array; Qiagen). Results were expressed as polymerase chain reaction (PCR) cycles to threshold and normalized to the average of 3 control genes, glyceraldehyde phosphate dehydrogenase (GAPDH), hypoxanthine phosphoribosyltransferase 1 (HPRT1) and β2-microglobulin (B2M). Secondary outcomes studied were 1-year mortality and long-term RV failure (RVF-LT). RESULTS:CCR3, CCR4, CCR6, CCR7 and CCR8 were downregulated in LVAD recipients with RVF. Within this cohort of patients, CCR4, CCR7 and CCR8 were further downregulated in those who required RV mechanical support. In addition, under-expression of CCR3 to CCR8 was independently associated with an increased risk of mortality at 1 year, even after adjusting for RVF. CCR expression did not predict RVF-LT in our patient cohort. CONCLUSIONS: Pre-LVAD CCR downregulation is associated with RVF and increased mortality after implant. Inflammatory signatures may play a major role in prognostication in this patient population.
Authors: G Gregory Neely; Keiji Kuba; Anthony Cammarato; Kazuya Isobe; Sabine Amann; Liyong Zhang; Mitsushige Murata; Lisa Elmén; Vaijayanti Gupta; Suchir Arora; Rinku Sarangi; Debasis Dan; Susumu Fujisawa; Takako Usami; Cui-ping Xia; Alex C Keene; Nakissa N Alayari; Hiroyuki Yamakawa; Ulrich Elling; Christian Berger; Maria Novatchkova; Rubina Koglgruber; Keiichi Fukuda; Hiroshi Nishina; Mitsuaki Isobe; J Andrew Pospisilik; Yumiko Imai; Arne Pfeufer; Andrew A Hicks; Peter P Pramstaller; Sai Subramaniam; Akinori Kimura; Karen Ocorr; Rolf Bodmer; Josef M Penninger Journal: Cell Date: 2010-04-02 Impact factor: 41.582
Authors: J K Damås; H G Eiken; E Oie; V Bjerkeli; A Yndestad; T Ueland; T Tonnessen; O R Geiran; H Aass; S Simonsen; G Christensen; S S Froland; H Attramadal; L Gullestad; P Aukrust Journal: Cardiovasc Res Date: 2000-09 Impact factor: 10.787
Authors: Jeffrey A Morgan; Pauline H Go; Linnea Xuereb; Babbaljeet Kaur; Silvy Akrawe; Hassan W Nemeh; Jamil Borgi; David E Lanfear; Celeste T Williams; Gaetano Paone Journal: Ann Thorac Surg Date: 2016-05-10 Impact factor: 4.330
Authors: P Aukrust; T Ueland; F Müller; A K Andreassen; I Nordøy; H Aas; J Kjekshus; S Simonsen; S S Frøland; L Gullestad Journal: Circulation Date: 1998-03-31 Impact factor: 29.690
Authors: Mark S Slaughter; Joseph G Rogers; Carmelo A Milano; Stuart D Russell; John V Conte; David Feldman; Benjamin Sun; Antone J Tatooles; Reynolds M Delgado; James W Long; Thomas C Wozniak; Waqas Ghumman; David J Farrar; O Howard Frazier Journal: N Engl J Med Date: 2009-11-17 Impact factor: 91.245
Authors: Joseph G Rogers; Javed Butler; Steven L Lansman; Alan Gass; Peer M Portner; Michael K Pasque; Richard N Pierson Journal: J Am Coll Cardiol Date: 2007-08-06 Impact factor: 24.094
Authors: Arne Yndestad; Alexandra Vanessa Finsen; Thor Ueland; Cathrine Husberg; Christen P Dahl; Erik Øie; Leif Erik Vinge; Ivar Sjaastad; Øystein Sandanger; Trine Ranheim; Kenneth Dickstein; John Kjekshus; Jan Kristian Damås; Arnt E Fiane; Denise Hilfiker-Kleiner; Martin Lipp; Lars Gullestad; Geir Christensen; Pål Aukrust Journal: PLoS One Date: 2012-03-12 Impact factor: 3.240
Authors: Merry L Lindsey; Yonggang Ma; Elizabeth R Flynn; Michael D Winniford; Michael E Hall; Kristine Y DeLeon-Pennell Journal: Biochim Biophys Acta Mol Basis Dis Date: 2018-09-20 Impact factor: 5.187